checkAd

     157  0 Kommentare Collection Sites Provides Update With January Sales of 73,973 Tests at an Average Price of $96 per Test - Seite 3

    For additional information, please contact:

    Doug Sommerville, CEO
    Doug.Sommerville@medivolve.ca

    For investing inquiries please contact:
    Evan Veryard
    Evan.veryard@medivolve.ca

    For US media enquires please contact:
    Veronica Welch
    veronica@vewprmedia.com
    +1-508-643-8000

    Cautionary Note Regarding Forward-looking Information

    This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to revenues earned by the Company and the number of tests conducted; the collectability of revenues; the expansion of COVID-19 testing sites; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

    Seite 3 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Collection Sites Provides Update With January Sales of 73,973 Tests at an Average Price of $96 per Test - Seite 3 To date Collection Sites has launched a total of 62 sites across its network with additional new openings in Texas, Florida, and North Carolina. Further, Medivolve will host a webinar today, Thursday, February 4th at 1 pm ET. TORONTO, Feb. 04, …